No profile data available.
Zhengye Biotechnology Holding Limited (ZYBT) is a healthcare company in the animal healthcare items industry, based in Jilin, China, with about 269 full-time employees.
It reported revenue of 186.36 million CNY for fiscal year 2024, down 12.0% from fiscal year 2023, and net income of 11.31 million CNY. Its market capitalization was $81.99 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in the People's Republic of China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs, as well as monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine.
Zhengye Biotechnology Holding reported 186.36 million CNY in revenue for fiscal year 2024, down 12.0% from 211.65 million CNY in fiscal year 2023.
$81.99 million as of October 9, 2026.
Listed companies of a similar size in the same industry (animal healthcare items) include Elanco Animal Health Incorporated (ELAN), Phibro Animal Health Corporation (PAHC), ImmuCell Corporation (ICCC), Provectus Biopharmaceuticals, Inc. (PVCT).